EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards

Steven R Baginski iD, Tobias Rautio iD, Lorna A Nisbet iD, Karin Lindbom, Xiongyu Wu iD, Johan Dahlén, Craig McKenzie iD, Henrik Gréen iD

Journal of Analytical Toxicology · 12.12.2023 · 47 (9) · 826-834

DOI: 10.1093/jat/bkad065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Analytical Toxicology, online erschienen am 25.09.2023. Verfasst von Steven R Baginski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Leverhulme Research Centre for Forensic Science, School of Science and Engineering, University of Dundee, Fleming Laboratory, Small's Wynd, Dundee DD…. Hauptthemen laut MEDLINE: Cannabinoid Receptor Agonists, Cannabinoids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Linköpings Universitet, Eurostars-3, Eurostars-2.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic cannabinoid receptor agonists (SCRAs) remain a major public health concern, with their use implicated in intoxications and drug-related deaths worldwide. Increasing our systematic understanding of SCRA metabolism supports clinical and forensic toxicology casework, facilitating the timely identification of analytical targets for toxicological screening procedures and confirmatory analysis. This is particularly important as new SCRAs continue to emerge on the illicit drug market. In this work, the metabolism of ADB-HEXINACA (ADB-HINACA, N-[1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-hexyl-1H-indazole-3-carboxamide), which has increased in prevalence in the United Kingdom and other jurisdictions, was investigated using in vitro techniques. The (S)-enantiomer of ADB-HEXINACA was incubated with pooled human hepatocytes over 3 hours to identify unique and abundant metabolites using liquid chromatography–quadrupole time-of-flight mass spectrometry. In total, 16 metabolites were identified, resulting from mono-hydroxylation, di-hydroxylation, ketone formation (mono-hydroxylation then dehydrogenation), carboxylic acid formation, terminal amide hydrolysis, dihydrodiol formation, glucuronidation and combinations thereof. The majority of metabolism took place on the hexyl tail, forming ketone and mono-hydroxylated products. The major metabolite was the 5-oxo-hexyl product (M9), while the most significant mono-hydroxylation product was the 4-hydroxy-hexyl product (M8), both of which were confirmed by comparison to in-house synthesized reference standards. The 5-hydroxy-hexyl (M6) and 6-hydroxy-hexyl (M7) metabolites were not chromatographically resolved, and the 5-hydroxy-hexyl product was the second largest mono-hydroxylated metabolite. The structures of the terminal amide hydrolysis products without (M16, third largest metabolite) and with the 5-positioned ketone (M13) were also confirmed by comparison to synthesized reference standards, along with the 4-oxo-hexyl metabolite (M11). The 5-oxo-hexyl and 4-hydroxy-hexyl metabolites are suggested as biomarkers for ADB-HEXINACA consumption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cannabinoid Receptor AgonistsCannabinoidsHumansTandem Mass SpectrometryMetabolomeReference StandardsHepatocytesAmidesKetonesMicrosomes, Liver

Substanzen

Cannabinoid Receptor AgonistsCannabinoidsAmidesKetones

Autor:innen und Institutionen

  • Leverhulme Research Centre for Forensic Science, School of Science and Engineering, University of Dundee, Fleming Laboratory, Small's Wynd, Dundee DD1 4HN, UK.
  • Department of Physics, Chemistry and Biology, Linköping University, Linköping 581 83, Sweden.
  • Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping 581 83, Sweden.
  • Chiron AS, Stiklestadveien 1, Trondheim 7041, Norway.
  • Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Artillerigatan 12, Linköping 587 58, Sweden.

ORCID-Profile: Steven R Baginski, Tobias Rautio, Lorna A Nisbet, Xiongyu Wu, Craig McKenzie, Henrik Gréen

Förderung

  • Linköpings Universitet
  • Eurostars-3
  • Eurostars-2
  • VINNOVA
  • Leverhulme Trust

Zitieren

APA

Baginski, S. R., Rautio, T., Nisbet, L. A., Lindbom, K., Wu, X., Dahlén, J., McKenzie, C., & Gréen, H. (2023). The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards. Journal of Analytical Toxicology, 47(9), 826-834. https://doi.org/10.1093/jat/bkad065

Vancouver

Baginski SR, Rautio T, Nisbet LA, Lindbom K, Wu X, Dahlén J, et al. The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards. Journal of Analytical Toxicology. 2023;47(9):826-834. doi:10.1093/jat/bkad065

BibTeX
@article{Baginski2023,
  author = {Baginski, Steven R and Rautio, Tobias and Nisbet, Lorna A and Lindbom, Karin and Wu, Xiongyu and Dahlén, Johan and McKenzie, Craig and Gréen, Henrik},
  title = {The metabolic profile of the synthetic cannabinoid receptor agonist ADB-HEXINACA using human hepatocytes, LC–QTOF-MS and synthesized reference standards},
  journal = {Journal of Analytical Toxicology},
  year = {2023},
  volume = {47},
  number = {9},
  pages = {826--834},
  doi = {10.1093/jat/bkad065}
}
Kostenlos starten →